CytomX Therapeutics is back in focus after recent Street research clustered around higher price targets, with several analysts flagging fresh US$2 and US$3.50 levels alongside a reaffirmed US$9.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results